Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database, Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry, Elizabeth Lorenzi, Thomas Clinch, Jacqueline M. Kraveka, William Ferguson, Valerie I. Brown, Don Eslin, Derek Hanson, Virginia Lynn Harrod, Michael Isakoff, Deanna Mitchell, Randal Wada, Peter E. Zage, Giselle Linda Saulnier Sholler, SIOP Annual Meeting, Barcelona, Spain, Sept 2022
